BD reports Q1 FY2023 revenue $4.6B (-2.8% as reported); adj. EPS $2.98; raises guidance

BECTON DICKINSON & CO

2023-Q1 EPS reported $1.70 revenue$4,586,000,000

Revenue of $4,586M decreased 2.8% as reported, increased 1.7% currency-neutral versus Q1 FY2022.
Base business (ex-COVID diagnostics) revenue grew 0.4% as reported, 5.2% currency-neutral.
GAAP diluted EPS from continuing operations $1.70; adjusted diluted EPS $2.98, down 6.0% YoY.
Company raises full-year fiscal 2023 revenue and adjusted EPS guidance.
Results exclude spun-off Diabetes Care business (Embecta) accounted as discontinued operations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BECTON DICKINSON & CO reported the first quarter of fiscal 2023 ended December 31, 2022 results: revenue $4.6 billion, EPS $1.70. Guidance raised.

Period: the first quarter of fiscal 2023 ended December 31, 2022
Revenue: $4.6 billion
EPS: $1.70
Guidance: raised
Result: reported results

Exact text from the filing

BD Reports First Quarter Fiscal 2023 Financial Results Execution of BD 2025 Strategy Delivering Consistent and Durable Performance • Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis • Revenue from base business (which excludes COVID-only diagnostic testing) grew 0.4% as reported, 5.2% currency-neutral • GAAP and adjusted diluted EPS from continuing operations of $1.70 and $2.98, respectively • Company raises full-year revenue and adjusted EPS guidance

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BECTON DICKINSON & CO filing history →

Source: SEC EDGAR

accession 0000010795-23-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.